NC
AVEO

Nexthera Capital’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Nexthera Capital’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-5,200
Closed -$190K – 55
2017
Q3 		$190K Buy
+5,200
New +$161K 0.05% 37
2016
Q3 		– Sell
-51,813
Closed -$498K – 42
2016
Q2 		$498K Buy
+51,813
New +$500K 0.43% 29

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Nexthera Capital's AVEO Position: Q4 2017 in Review

Nexthera Capital sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2017, closing a stake of 5,200 shares — an estimated $190K sold.

Nexthera Capital first reported a position in AVEO in Q2 2016 and held it in 2 quarters. The position peaked at $498K in Q2 2016. 84 funds tracked by Wall St. Rank hold AVEO as of Q4 2017.

  • Nexthera Capital reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2017 after selling out during the quarter.
  • Nexthera Capital sold 5,200 AVEO Pharmaceuticals, Inc. shares in Q4 2017, an estimated $190K.
  • Nexthera Capital first reported a position in AVEO Pharmaceuticals, Inc. in Q2 2016 and held it in 2 quarters.
  • Nexthera Capital's AVEO Pharmaceuticals, Inc. position peaked at $498K in Q2 2016.
  • 84 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2017.

Based on Nexthera Capital's 13F filing for Q4 2017, filed 14 Feb 2018.